NCT05021250View on ClinicalTrials.gov

SBRT With DIBH for HCC After TACE and Lipiodol Marking

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

April 30, 2024

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Lipiodol marking

HCC patients treated with TACE and the tumor marked with lipiodol.

Trial Locations (1)

100021

Bo Chen, Beijing

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER